News

Discover the latest STENTYS news.

  • 2017

     

    STENTYS is strengthening its Board by co-opting two new independent members

    03/04/2017

    • Prof. Christian Spaulding, Head of the Interventional Cardiology department at the Georges-Pompidou European Hospital in Paris

    • Sophie Baratte, CEO of medical technology company Cellnovo

    PARIS - April 3, 2017 – 6 pm CET - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the XPOSITION S self-apposing coronary stent, today announces that the STENTYS Board of Directors has decided to co-opt Professor Christian Spaulding and Mrs. Sophie Baratte as independent Board members.

    Download File
     

    STENTYS Completes Enrollment of the TRUNC Study

    27/07/2017

    STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy  of Xposition S in Left Main Artery Lesions    

    200 patients enrolled in the TRUNC clinical trial      

    PARIS – July 27, 2017 – 6.15 pm CEST – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the Xposition S Sirolimus-eluting self-apposing coronary stent, today announces that the enrollment of the 200 patients for the TRUNC trial has been completed as scheduled. 

    Download File
     

    Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

    24/05/2017

    STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes    

    PARIS – May 24, 2017 - 7.30 am CEST - STENTYS (FR0010949404 - STNT), a medical technology company commercializing the Xposition S Sirolimus-eluting self-apposing coronary stent, today announced that it has reported final follow-up results of two clinical studies featuring STENTYS stents during the annual EuroPCR meeting held in Paris last week.

    Download File
     
  • 2016

     

    STENTYS Enrolls First Patient in Left Main Clinical Trial

    19/07/2016

    STENTYS Enrolls First Patient in  Left Main Clinical Trial    

    The TRUNC study is designed to evaluate Xposition S efficacy  in 200 patients suffering from Left Main disease     

    PRINCETON, N.J. and PARIS – July 19, 2016 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that it has commenced enrolling patients in the TRUNC trial, which is designed to evaluate the long-term safety and efficacy of the Xposition S stent in the treatment of unprotected left main coronary artery disease. 

    Download File
     

    STENTYS: Appointment of Cardiovascular Device Veteran as New CEO

    04/07/2016

    STENTYS: Appointment of Cardiovascular Device Veteran  as New CEO      

    • Christophe Lottin, ex second in command at stent company Hexacath, brings 20 years of sales and management experience 
    • Gonzague Issenmann recruited his successor to ensure the company he has created continues to thrive     

    PRINCETON, N.J. and PARIS – July 4, 2016 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that the Board of Directors has appointed Christophe Lottin as the new Chief Executive Officer of the Company. Gonzague Issenmann has organized his succession and will ensure a smooth transition over the next quarter.  

    Download File
     

    STENTYS Announces CE Marking of its longest Xposition stent

    08/06/2016

    STENTYS Announces CE Marking  of its longest Xposition stent   

    Portfolio expansion with the addition of a 37 mm stent  designed for long coronary lesions   

    PRINCETON, N.J. and PARIS – June 8, 2016 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that it has received CE Marking for the longest version of its Xposition S Sirolimuseluting self-apposing stent.   

    Download File
     

    STENTYS Announces the CE Marking of the Self-Apposing Stent for Left Main Coronary Artery Disease

    21/03/2016

    STENTYS Announces the CE Marking of the Self-Apposing Stent for Left Main Coronary Artery Disease     

    PRINCETON, N.J. and PARIS – March 21, 2016 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced that Xposition S, the Sirolimus-eluting Self-Apposing stent, received CE Marking for the treatment of Unprotected Left Main Coronary artery disease on the basis of the results from a study published last year in the peer-reviewed journal Catheterization and Cardiovascular Interventions (CCI).

    Download File
     

    Results of Self-Apposing Sirolimus-Eluting Stent Trial Published in EuroIntervention

    29/02/2016

    STENTYS: Results of Self-Apposing Sirolimus-Eluting Stent Trial Published in EuroIntervention   

    APPOSITION IV trial demonstrated superior apposition and faster healing  than with conventional stents   

    PRINCETON, N.J. and PARIS - February 29, 2016 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that the results of the APPOSITION IV trial, which compared the STENTYS SelfApposing Sirolimus-eluting coronary stent to the Medtronic Resolute® stent in patients presenting with ST-segment elevation myocardial infarction (STEMI), were published in the February issue of EuroIntervention , the official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

    Download File
     

    Launch of the Commercialization of the first Self-Expanding Drug-Eluting stent for the Below-The-Knee Indication

    08/02/2016

    STENTYS initiates the Commercialization  of the first Self-Expanding Drug-Eluting stent  for the Below-The-Knee Indication     

    PRINCETON, N.J. and PARIS – February 8, 2016 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces the first distribution agreements for its drug-eluting stent for treating BTK (Below-The Knee) arteries in Germany and Belgium, making it the first self-expanding drugeluting stent commercialized for this indication in Europe. 

    Download File
     

    STENTYS: First Intervention with the Self-Apposing Drug-Eluting Stent for Lower Limbs broadcasted live at LINC international congress

    28/01/2016

    STENTYS: First Intervention with the Self-Apposing  Drug-Eluting Stent for Lower Limbs  broadcasted live at LINC international congress   

    Two procedures successfully performed at Leipzig University hospital   

    PRINCETON, N.J. and PARIS - January 28, 2016 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that the first interventions using its self-expanding drug-eluting stent to treat BTK (below-the-knee) arterial disease have been performed during two live-case sessions broadcasted during LINC, the Leipzig Interventional Course, the largest congress on peripheral pathologies. 

    Download File
     
  • 2015

     

    Enrollment Completion of MiStent Randomized Trial against Xience

    09/12/2015

    STENTYS: Enrollment Completion of MiStent Randomized Trial against Xience     DESSOLVE III clinical trial enrolled 1,400 “all-comers” patients 

    Primary endpoint results to be announced in H1 2017     

    PRINCETON, N.J. and PARIS - December 9, 2015 - STENTYS (FR0010949404 - STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, announced today the completion of patient enrollment in DESSOLVE III, a 1,400 patient randomized clinical trial comparing MiStent SES® Sirolimus Eluting Absorbable Polymer Coronary Stent System to Abbott’s Xience® stent.

     

    STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years

    12/10/2015

    STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years   

    Follow-up imaging data from APPOSITION IV study to be presented at TCT conference in San Francisco   

    PRINCETON, N.J. and PARIS – October 12, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that three-year follow-up imaging data from the STENTYS arm of the APPOSITION IV clinical study confirms the long-term performance of the sirolimus-eluting Self-Apposing stent. The data will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, CA.

    Download File
     

    STENTYS Receives CE Mark for Self-Apposing Stent in Lower Limb Artery Disease

    28/09/2015

    STENTYS Receives CE Mark for Self-Apposing Stent in Lower Limb Artery Disease   

    PRINCETON, N.J. and PARIS – September 28, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced that the Company’s Drug-Eluting stent received CE Mark for treatment of belowthe-knee (BTK) arteries, making STENTYS’ product the first self-expanding and drug-eluting stent with regulatory approval in Europe for this indication. 

    Download File
     

    First Clinical Experience with Xposition shows 100% implantation success, Confirms Ease of Use

    19/05/2015

    STENTYS: First Clinical Experience with Xposition shows 100% implantation success, Confirms Ease of Use    

    Results of SETUP Trial presented at EuroPCR and Published on-line  in EuroIntervention      

    PRINCETON, N.J. and PARIS – May 19, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced that the findings of the first Xposition® clinical experience, as part of the SETUP trial, were presented at the EuroPCR conference. The results of this study were also published today in the online edition of EuroIntervention.

    Download File
     

    STENTYS’ Next-Generation of Self-Apposing Stent System Receives CE Marking Ahead of Plan

    28/04/2015

    STENTYS’ Next-Generation of Self-Apposing Stent System  Receives CE Marking Ahead of Plan   

    Xposition S™ combines STENTYS Sirolimus-eluting Stent with New and Unique Delivery Catheter that Replicates Conventional Stent Implantation Technique   

    Product to be Introduced at EuroPCR on May 19th     

    PRINCETON, N.J. and PARIS – April 28, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced it received CE Marking for its new Self-Apposing stent system ahead of plan, which will allow the Company to market the new products in Europe and in all the other countries where this certification is recognized. STENTYS will officially launch Xposition S™ at the EuroPCR conference on May 19, 2015.

    Download File
     

    Results of largest STENTYS Stent Trial in Myocardial Infarction Published in EuroIntervention

    23/02/2015

    Results of largest STENTYS Stent Trial in Myocardial Infarction Published in EuroIntervention   APPOSITION III showed excellent safety profile of the Self-Apposing technology     

    PRINCETON, N.J. and PARIS – February 23, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced that the one-year clinical outcomes of the APPOSITION III registry (see the press release from March 9, 2013), which studied the STENTYS Self-Apposing coronary stent in patients presenting with ST-segment elevation myocardial infarction (STEMI), have been published in EuroIntervention , the official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

    Download File
     

    New Self-Apposing Stent Study in Left Main Coronary Artery

    12/02/2015

    STENTYS Announces the Publication of New Self-Apposing Stent Study in Left Main Coronary Artery    

    Study published online in the Catheterization and Cardiovascular Interventions Journal showed superiority of Self-Apposing technology in Opening the Heart’s Main Artery   

    PRINCETON, N.J. and PARIS – February 12, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced that new data on the Self-Apposing stent in the challenging treatment of the Left Main coronary artery was published in the peer-reviewed journal C a t h e t e r i z a t i o n a n d Cardiovascular Interventions (CCI) and the authors concluded that the STENTYS DES offers a valid treatment alternative for this indication.  

    Download File
     

    STENTYS Expands Benefits of First Drug-Eluting, Self-Expanding Stent to Lower Limb Artery Disease

    28/01/2015

    STENTYS Expands Benefits of First Drug-Eluting,  Self-Expanding Stent to Lower Limb Artery Disease Clinical Trial Found STENTYS Treatment Prevented   Amputation in 99% of Cases   

    PRINCETON, N.J. and PARIS – January 28, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced that its unique Drug-Eluting and Self-Expanding stent was evaluated in 70 patients suffering from critical limb ischemia (CLI) and prevented foot amputation in 99% of them. 

    Download File
     
  • 2014

     

    STENTYS enrichit son offre de produits à toutes les indications coronaires par un accord exclusif avec Micell pour distribuer son stent actif innovant

    03/11/2014

    STENTYS Expands Product Offering To All Coronary Stent Indications Through Exclusive Agreement With Micell To Distribute Its Novel Drug-Eluting Stent
     

    PRINCETON, N.J. and PARIS – November 3, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced it has entered into a five year agreement with Micell Technologies Inc. to be the exclusive distributor of the MiStent coronary stent worldwide (excluding the United States, Canada, China, South Korea and Japan).

    Download File
     

    STENTYS Reaches 10,000 Self-Apposing Stent implantations

    03/09/2014

    STENTYS Reaches 10,000  Self-Apposing Stent implantations

    PRINCETON, N.J. and PARIS – September 3rd, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced that the Self-Apposing stent has been implanted over 10,000 times in patients worldwide. This milestone further illustrates the popularity of STENTYS’ technology among cardiologists in Europe and a growing number of regions globally.
     

    Download File
     

    STENTYS to Acquire Stent Delivery Technology for Its Next-Generation of Self-Apposing Stents

    04/06/2014

    STENTYS to Acquire Stent Delivery Technology for Its Next-Generation of Self-Apposing Stents 


    Unique Delivery Catheter Replicates 

    Conventional Stent Implantation Technique

    PRINCETON, N.J. and PARIS – June 4, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced the signing of the acquisition agreement of Cappella Peel Away Inc. (Delaware, USA) and its assets relating to a novel stent delivery system. The acquisition is subject to closing conditions.

    Download File
     

    STENTYS: Journal of the American College of Cardiology Publication Shows Malapposition Influences Death from Early Stent Thrombosis

    07/05/2014

    STENTYS: Journal of the American College of Cardiology Publication Shows Malapposition Influences Death from Early Stent Thrombosis 

    Study conducted by Dr Virmani further supports the Self-Apposing technology’s scientific rationale 

    PRINCETON, N.J. and PARIS – May 6, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® Stent for treating acute myocardial infarction (AMI), today announced the publication of an article in the Journal of the American College of Cardiology (JACC) entitled, "Causes of Early Stent Thrombosis in Patients Presenting with Acute Coronary Syndrome: An Ex Vivo Human Autopsy Study."
     

    Download File
     

    STENTYS Expands Marketing of its Stents in Asia

    08/01/2014

    STENTYS Expands Marketing of its Stents in Asia 
    Distribution agreements signed in Singapore, Hong Kong and Malaysia

    PRINCETON, N.J. and PARIS - January 8, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® Stent for treating acute myocardial infarction (AMI), today announced the signing of the first distribution partnerships for its stents in Asia.
     

    Download File
     

    STENTYS Expands Marketing of the Self-Apposing Stent in South America

    09/07/2014

    STENTYS Expands Marketing of the Self-Apposing Stent  in South America 


    PRINCETON, N.J. and PARIS – July 9, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world’s first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announced its first distribution contracts in South America.
     

    Download File
     

    STENTYS appoints Medical Device Executive to its Board of Directors

    10/04/2014

    STENTYS appoints Medical Device Executive to its Board of Directors

    Dianne Blanco, CEO of Orteq, brings 20 years of medical technology management experience

    PRINCETON, N.J. and Paris - April 10, 2014 - STENTYS (FR00A0949404 - STNT), a medical technology company commercializing the world's first and only Self-Apposing®  stent to treat acute myocardial infarction (AMI), today announced that Dianne Blanco has been appointed as a Director to replace the representative from Omnes Capital venture capital fund. 

    Download File
     

    STENTYS Stent continues to show low mortality two years after treatment of a heart attack

    16/09/2014

    STENTYS Stent continues to show low mortality two years after treatment of a heart Attack

    Final 2 Year Results from APPOSITION III Study Pres ented Today at TCT Conference in Washington, D.C 


    PRINCETON, N.J. and PARIS – September 16, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announced the results of the 1,000 patient APPOSITION III clinical study at two years after the treatment of a severe heart attack. 
     

    Download File
     

    STENTYS Sirolimus-Eluting Stent Demonstrates Best in Class Efficacy for Heart Attack Patients

    20/05/2014

    STENTYS Sirolimus-Eluting Stent Demonstrates Best in Class Efficacy for Heart Attack Patients

    Final Results from APPOSITION IV Study Presented at EuroPCR: 

    - No late loss and perfect strut coverage at 9-months 

    - Faster arterial healing compared to conventional drug-eluting stents

     
    PRINCETON, N.J. and PARIS – May 20, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today presented final results from the APPOSITION IV study of its new Self-Apposing sirolimus-eluting stent (SES) during the Hotline session at the EuroPCR conference in Paris.

    Download File
     

    STENTYS Wins Large Regional Tender in Middle East

    20/10/2014

    STENTYS Wins Large Regional Tender in Middle East 


    PRINCETON, N.J. and PARIS – October 20, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announced that the 2014 SGH tender has awarded more than 1,000 coronary stents to STENTYS.

    Download File
     

    STENTYS Adds Branch Office in Dubai

    25/09/2014

    STENTYS Adds Branch Office in Dubai

    PRINCETON, N.J. and PARIS – September 25, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announces the creation of a branch office in Dubai (United Arab Emirates).

    Download File
     

    STENTYS Self-Apposing Stent Featured Prominently at 2014 EuroPCR Conference

    27/05/2014

    STENTYS Self-Apposing Stent Featured Prominently  at 2014 EuroPCR Conference

    Over 20 case presentations  

    3 clinical trials in “Hotline”

    Late Breaking sessions 

    2 dedicated symposia


    PRINCETON, N.J. and PARIS – May 27, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today reported on multiple sessions, symposia and case presentations featuring STENTYS stents during the annual EuroPCR meeting held in Paris last week.
     

    Download File
     

    STENTYS’ Sirolimus-Eluting Stent Receives CE Marking

    27/10/2014

    STENTYS’ Sirolimus-Eluting Stent Receives CE Marking

    PRINCETON, N.J. and PARIS – October 27, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces it received CE Marking for its Sirolimus-Eluting Stent (SES). The CE Marking will allow the Company to market its SES in Europe immediately and, starting in 2015, in the many other countries where the Company has commercial activity. 
     

    Download File
     

    STENTYS’ Self-Apposing Stent Featured in New Article Published by the Journal of the American College of Cardiology

    29/04/2014

    STENTYS’ Self-Apposing Stent Featured in New Article Published by the Journal of the American College of Cardiology

    STENTYS highlighted as a solution to minimize stent malapposition in clinical practice

    PRINCETON, N.J. and PARIS – April 29, 2014 — STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world’s first and only Self-Apposing® Stent for treating acute myocardial infarction (AMI), today announced that the Journal of the American College of Cardiology (JACC) published a “State-of-the-Art Paper” entitled “Mechanisms, Pathophysiology, and Clinical Aspects of Incomplete Stent Apposition,” which highlights STENTYS’ Self-Apposing Stent among novel devices to minimize stent malapposition, also known as incomplete stent apposition (ISA), in clinical practice.

     

    Download File
     

    STENTYS Reallocates Resources to focus on its Advanced Drug-Eluting Stent Progra

    31/07/2014

    STENTYS Reallocates Resources to focus on its Advanced 

    Drug-Eluting Stent Program

    PRINCETON, N.J. and PARIS – July 31, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announces that it has discontinued enrollment of the APPOSITION V trial evaluating its bare metal stent (BMS) and that the Company will instead direct those financial resources towards developing its next-generation Sirolimus-eluting stents (SES) on a new delivery catheter. 

    Download File
     
  • 2013

     

    STENTYS clinical study demonstrating superiority of SelfApposing® stents over conventional stents published in American College of Cardiology journal

    03/01/2013

    STENTYS clinical study demonstrating superiority of SelfApposing® stents over conventional stents published in American College of Cardiology journal

    APPOSITION II randomized study showed 28% malapposition in conventional stents versus 0% in STENTYS stents

    PRINCETON, N.J. and PARIS – January 3, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), announced today that results from the foundational APPOSITION II clinical trial were published in the December issue of the American College of Cardiology’s journal, JACC Cardiovascular Interventions . The manuscript, also available online is titled, “Self-Expanding Versus Balloon-Expandable Stents in Acute Myocardial Infarction: Results from the APPOSITION II Study”. 

    Download File
     

    STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials

    09/03/2013

    STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials

    One - year APPOSITION III results in 1,000 heart attack patients presented at ACC.13

     
    PRINCETON, N.J. and PARIS – March 9, 2013 – STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today one-year results of the APPOSITION III clinical trial in 1,000 patients post treatment of a severe heart attack at ACC.13, the American College of Cardiology’s Scientific Session & Expo. 
     

    Download File
     

    STENTYS Self-Apposing Stent Approved in Europe for Additional Coronary Indications

    10/07/2013

    STENTYS Self-Apposing Stent Approved in Europe for Additional Coronary Indication

    New market segments represent 10% of all coronary interventions

     
    PRINCETON, N.J. and PARIS – July 10, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today that it received approval from its European Notified Body to expand the CE Mark indications of the Self-Apposing stent.
     

    Download File
     

    STENTYS Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial

    20/05/2013

    STENTYS Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial 

    PRINCETON, N.J. and PARIS – May 20, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today that the first patient was enrolled in APPOSITION V, the pivotal FDA-approved IDE trial which will enable the Company to apply for marketing approval of the Self-Apposing Stent in the United States.
     

    Download File
     

    STENTYS to Present first results of Sirolimuseluting Self-Apposing® Stent at TCT Conference

    21/10/2013

    STENTYS to Present first results of Sirolimuseluting Self-Apposing® Stent at TCT Conference

    PRINCETON, N.J. and PARIS – October 21, 2013 – STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced that the 4-month results of the APPOSITION IV trial will be disclosed during the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. Dr Robert-Jan van Geuns, M.D., Ph.D., of Erasmus MC (Rotterdam, the Netherlands) and co-Principal Investigator, will present “Sirolimus-Eluting Self-Apposing Stent: Preliminary Results of the APPOSITION IV Study and Future Developments”, during a Satellite Symposium on October 29 at 7:00am

    Download File
     

    Further Data on STENTYS Self-Apposing Stent Reinforces Strength of Clinical Results

    22/05/2013

    Further Data on STENTYS Self-Apposing Stent Reinforces Strength of Clinical Results

    New Sub - group Analysis of APPOSITION III Presented at EuroPCR  in Paris

     
    PRINCETON, N.J. and PARIS – May 22, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today new one-year data from the APPOSITION III clinical trial at the international EuroPCR conference in Paris. APPOSITION III was designed to assess the long-term performance of STENTYS Self-Apposing Stents in routine clinical practice in Europe among 1,000 patients suffering a heart attack (ST-elevation myocardial infarction or STEMI).
     

    Download File
     

    STENTYS to Present Final Results From 1,000 Heart Attack Patient Study at ACC.13

    26/02/2013

    STENTYS to Present Final Results From 1,000 Heart Attack Patient Study at ACC.13

    Educational Symposium Also to Highlight FDA - A pproved U.S. P ivotal S tudy  for Self - Apposing ® S tent in STEMI Patients 

    PRINCETON, N.J. and PARIS – February 26, 2013 – STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today that results for the primary endpoint in the APPOSITION III study (MACE at one year on 1,000 STEMI patients) will be presented during ACC.13, the American College of Cardiology’s Scientific Session & Expo, March 9-11, 2013 in San Francisco. Prof. Gilles Montalescot, M.D., Ph.D, Head of the Cardiac Care Unit at Pitié-Salpêtrière Hospital (Paris), will present “One Year Clinical Results on 1,000 STEMI Patients Treated With a Self-Expanding Coronary Stent (APPOSITION III)” during Session #2667 of the Featured Clinical Research I: Interventional session on Saturday, March 9, 2013 at 3:00 p.m. 

    Download File
     

    STENTYS Sirolimus-eluting stent demonstrates faster arterial healing than conventional drug-eluting stent

    29/10/2013

    STENTYS Sirolimus-eluting stent  demonstrates faster arterial healing  than conventional drug-eluting stentS

    4 - month results of APPOSITION I V Study presented at TCT 2013 


    PRINCETON, N.J. and PARIS – October 29, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today results from the 4-month arm of the APPOSITION IV study of its new Self-Apposing Sirolimus-eluting stent during the TCT (Transcatheter Cardiovascular Therapeutics) conference. 
     

    Download File
     

    STENTYS Self-Apposing Stent performs well in new coronary indications

    30/10/2013

    STENTYS Self-Apposing Stent performs well in new coronary indications

    Two stud ies assessing STENTYS in indications  outside of heart attacks presented at TCT 2013 


    PRINCETON, N.J. and PARIS – October 30, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced new data this week in indications outside of myocardial infarction. Results from the OPEN II study and a series from the Amsterdam Medical Center were presented during the TCT (Transcatheter Cardiovascular Therapeutics) conference in San Francisco.

    Download File
     
  • 2012

     

    STENTYS concludes clinical trial ahead of plan

    01/02/2012

    STENTYS concludes clinical trial ahead of plan

    Fast enrollment underscores increasing technology adoption  among 50 European hospitals in APPOSITION III study 


    PRINCETON, N.J., and PARIS, Feb. 1st, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing™ Stent to treat Acute Myocardial Infarction (AMI), announced today that the “APPOSITION III” clinical study successfully enrolled 1,000 patients suffering from a severe heart attack and that the final results of the examination 30 days after treatment will be presented during the upcoming EuroPCR international cardiology congress.

    Download File
     

    Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications

    08/02/2012

    Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications

    More patients to benefit from STENTYS technology 


    PRINCETON, N.J., and PARIS,  February 8, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing™ Stent to treat Acute Myocardial Infarction (AMI), announced today that the higher-price reimbursement in Germany received in 2011 for its drug-eluting stent was expanded to all coronary indications in 2012, allowing even more patients to benefit from its technology

    Download File
     

    STENTYS starts clinical trial to broaden portfolio with new drug-eluting stent

    14/06/2012

    STENTYS starts clinical trial to broaden portfolio with new drug-eluting stent

    APPOSITION IV clinical study to compare STENTYS new Sirolimus-DES over Medtronic DES

    PRINCETON, N.J., and PARIS, June 14, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing® Stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the first patient in its APPOSITION IV clinical study using its new Self-Apposing® Sirolimus-eluting stent. The randomized study will enroll 150 heart attack patients who will be treated with either the STENTYS stent or Medtronic’s Resolute® drug-eluting stent, and will compare stent apposition in both groups at 4 and 9 months after treatment.

    Download File
     

    STENTYS expands its product offerings for treating heart attacks

    14/05/2012

    STENTYS expands its product offerings for treating heart attacks

    PRINCETON, N.J., and PARIS, May 14, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing® Stent to treat Acute Myocardial Infarction (AMI), announced today that it is launching a thrombectomy device (aspiration catheter) called STENTYS AC. 
     

    Download File
     

    STENTYS to Present One-Year Interim Results From APPOSITION III Study at TCT Conference

    15/10/2012

    STENTYS to Present One-Year Interim Results From APPOSITION III Study at TCT Conference

    Satellite Symposium Also to Highlight Pr oposed U.S. Clinical Trial Program for Self-Apposing ® Stent in STEMI Patients  

    PRINCETON, N.J. and PARIS – October 15, 2012 – STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat acute myocardial infarction (AMI), announced today that one-year interim results from the APPOSITION III study will be presented during the Transcatheter Cardiovascular Therapeutics (TCT) conference, October 22-26, 2012 in Miami. Prof. Harald Mudra, M.D., Ph.D., of Klinikum Neuperlach (Munich, Germany) will present the results during the morning spotlight session “Primary PCI for STEMI: Drugs, Devices, and Technique Controversies” on Thursday, October 25, 2012 at 9:58 a.m.

    Download File
     

    STENTYS Self-Apposing® Stent shows very low mortality at one month in 1,000 high risk heart attack patients

    16/05/2012

    STENTYS Self-Apposing® Stent shows very low mortality  at one month in 1,000 high risk heart attack patients

    APPOSITION III study results reveal mortality at 1.2%  compared to 3.5% in pooled analysis of conventional stents
     

    PRINCETON, N.J., and PARIS, May 16, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing® Stent to treat Acute Myocardial Infarction (AMI), announced today the definite results on the 1,000 patient APPOSITION III clinical study at one month after treatment of a severe heart attack.

    Download File
     

    STENTYS Receives FDA Approval to Initiate First U.S. Clinical Trial With Self-Apposing® Stent

    22/10/2012

    STENTYS Receives FDA Approval to Initiate First U.S. Clinical Trial With Self-Apposing® Sten

    PRINCETON, N.J. and PARIS – October 22, 2012 – STENTYS (FR0010949404 – STNT), a medical technology company that is commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), announced today that it has received Investigational Device Exemption (IDE) approval from the Food and Drug Administration (FDA) to conduct a pivotal clinical trial in the United States which, if successfully completed, will enable the Company to apply for marketing approval of the STENTYS SelfApposing stent. 

    Download File
     

    STENTYS Self-Apposing® Stent continues to demonstrate low mortality at one year in APPOSITION III trial

    22/10/2012

    STENTYS Self-Apposing® Stent continues to demonstrate low mortality at one year  in APPOSITION III trial

    Interim results to be reported at TCT 2012 

    PRINCETON, N.J. and PARIS – October 22, 2012 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), announced today the interim results of the APPOSITION III clinical trial for the first 600 patients at one year post treatment of a severe heart attack.

    Download File
     

    STENTYS Self-Apposing technology supported by breaking new scientific evidence

    26/03/2012

    STENTYS Self-Apposing technology supported by  breaking new scientific evidence

    Study points to stent sizing errors  as primary cause of heart attack récurrences


    PRINCETON, N.J., and PARIS, March 26, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing™ Stent to treat Acute Myocardial Infarction (AMI), announced today that the scientific rationale of its technology has been strongly supported by the conclusions of a new study by world renowned pathologist Dr. Renu Virmani (CVPath Institute, Gaithersburg, Md.), presented today at the ACC annual meeting in Chicago

    Download File
     

    STENTYS Launches New Stent-Delivery System to Facilitate Implantation in More Complex Vessel Anatomies

    26/09/2012

    STENTYS Launches New Stent-Delivery System to Facilitate Implantation in More Complex Vessel Anatomies

    PRINCETON, N.J. and PARIS – September 26, 2012 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today the European commercial release of an enhanced stent-delivery system for its SelfApposing® stent.

    Download File
     
  • 2011

     

    STENTYS enrolls first 250 patients, half of Apposition III study of its Self-Apposing Stent for treatment of Heart Attacks

    02/05/2011

    STENTYS enrolls first 250 patients, half of Apposition III study of its Self-Apposing Stent for treatment of Heart Attacks

    PRINCETON, N.J., and PARIS, May 2, 2011 — STENTYS S.A. (STNT.PA), a medical technology company that is commercializing a new generation of innovative stents to treat Acute Myocardial Infarction (AMI), announced today that it has reached the mid-point of its international APPOSITION III study of its Self-Apposing Stent, with 250 patients now enrolled out of a total of 500. The trial primary endpoint is Major Adverse Cardiac Events (MACE) at 12 months post-procedure.

    Download File
     

    STENTYS recruits Country Managers for France and Italy

    08/06/2011

    STENTYS recruits Country Managers for France and Italy 

    STENTYS (FR0010949404 - STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it is starting the marketing of the STENTYS stents in France and Italy.

     

    Download File
     

    Outstanding interim results of STENTYS international clinical study of 600 heart attack patients

    08/11/2011

    Outstanding interim results of STENTYS international clinical study of 600 heart attack patients

    Lower rate of adverse events for STENTYS Self-Apposing™ Stent compared to reported results of conventional stents   


    PRINCETON, N.J., and PARIS, Nov. 8, 2011 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing™ Stent to treat Acute Myocardial Infarction (AMI), disclosed today data on 600 patients from its ongoing “APPOSITION III” international clinical study who underwent an examination 30 day after treatment of a severe heart attack. 
     

    Download File
     

    STENTYS Self-Apposing Stents in “perfect apposition to vessels” after treating patients with heart attacks

    12/10/2011

    STENTYS Self-Apposing Stents in “perfect apposition to vessels”  after treating patients with heart attacks

    “APPOSITION I” study published in leading medical journal EuroIntervention 


    PRINCETON, N.J., and PARIS, Oct. 12, 2011 — STENTYS S.A. (STNT.PA), a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today the publication of the results of the “APPOSITION I” clinical study results in the September issue of the medical journal EuroIntervention,

    Download File
     

    Over 1000 patients have benefited from STENTYS Self-Apposing technology

    15/09/2011

    Over 1000 patients have benefited from STENTYS Self-Apposing technology 

    PRINCETON, N.J., and PARIS, Sept.15, 2011 - STENTYS S.A (FR0010949404, STNTP.PA), a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that its Self-Apposing Stent has been implanted into more than 1000 patients internationally. 

     

    Download File
     

    Stenting in STEMI: Does Size Matter?

    16/05/2011

    Stenting in STEMI: Does Size Matter?

    STENTYS® Self-Apposing™ Stent for STEMI and Complex Anatomy 


    EuroPCR Symposium, Thursday, 19th May, 12:00-13:30, Room 342AB
     

    Chairmen: Prof. Patrick W. Serruys, M.D., Maurice Buchbinder, M.D.,  


    PRINCETON, N.J., and PARIS, May 16, 2011 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), is hosting a key symposium at this week’s EuroPCR congress. The symposium — “Does Size Matter?  STENTYS® Self-Apposing™ Stent for STEMI and Complex Anatomy”—will be chaired by two internationally renowned cardiologists: Prof. Patrick W. Serruys, M.D. and Maurice Buchbinder, M.D. Registered participants of the EuroPCR congress are eligible to attend.

    Download File
     

    STENTYS expands operations into four additional European countries

    17/03/2011

    STENTYS expands operations into four additional  European countries

    PRINCETON, N.J., and PARIS, March 17, 2011 — STENTYS S.A. (STNT.PA), a medical technology company that is commercializing a new generation of innovative stents to treat acute myocardial infarction (AMI), announced today the launch of the STENTYS stents in four additional European countries: Scandinavia, Spain, Switzerland and Poland.  

     

    Download File
     

    STENTYS joins Stent for Life Initiative to expand optimal heart attack treatment across Europe

    18/05/2011

    STENTYS joins Stent for Life Initiative to expand optimal heart attack treatment across Europe

    PRINCETON, N.J., and PARIS, May 18, 2011 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has joined the Stent for Life (SFL) Initiative as a key industry partner.

    Download File
     

    Prof. Gilles Montalescot joins STENTYS Scientific Advisory Board

    20/06/2011

    Prof. Gilles Montalescot  joins STENTYS Scientific Advisory Board

    PRINCETON, N.J., and PARIS, June 20, 2011 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that Gilles Montalescot, M.D., PhD, has joined its Scientific Advisory Board (SAB).

    Download File
     

    STENTYS compeltes enrollement of APPOSITION III study for its Self-Apposing Stent to Treat Heart Attacks

    21/09/2011

    STENTYS compeltes enrollement of APPOSITION III study for its Self-Apposing Stent to Treat Heart Attacks 

    PRINCETON, N.J, and PARIS, Sept. 21, 2011 - S.A. (STNT.PA), a medical technology company that is commercializing the world's first and only self-apposing stent tp treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.

     

    Download File
     

    Increased reimbursement of STENTYS drug-eluting stent in Germany

    23/02/2011

    Increased reimbursement of STENTYS  drug-eluting stent in Germany

    PRINCETON, N.J., and PARIS, Feb. 23, 2011 — STENTYS S.A. (STNT.PA) announced today that it has received a higher price reimbursement in Germany for its drug-eluting stent

    Download File
     

    Revenues for the 1 half of 2011

    26/07/2011

    Revenues for the 1 half of 2011

    - Further buoyant increase in activity

    - First sales related to specific reimbursment in Germany (NUB)

    STENTYS (FR0010949404 - STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), today reports its revenues for the 1 half to 30 June 2011.

    Download File
     

    STENTYS reports six-month 2011 Financial results

    31/08/2011

    STENTYS reports six-month 2011 Financial results

    - Revenues soar eight-fold vs. 1H 2010

    - Cash position remains strong

    -Marketing presence in eight EU countries

    STENTYS (FR0010949404 - STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), today reported its Financial results for the six months ending 30 June 2011.

     

    Download File
     
  • 2010

     

    Stentys self-expanding stent receives CE Marking to treat acute coronary syndrome (ACS)

    05/03/2010

    Stentys self-expanding stent receives CE Marking to treat acute coronary syndrome (ACS)
     

    PRINCETON, N.J., and PARIS, March 5, 2010—Medical device pioneer Stentys announced today that it has received CE Marking for its self-expanding and disconnectable stent to treat acute coronary syndrome (ACS). 

    Download File
     

    Stentys appoints Stanislas Piot as Chief Financial Officer

    02/09/2010

    Stentys appoints Stanislas Piot as Chief Financial Officer

    PRINCETON, N.J., and PARIS, Sept. 2, 2010—Stentys, which develops innovative stents to treat Acute Myocardial Infarction (AMI), announced today the appointment of Stanislas Piot as Chief Financial Officer, effective immediately.

    Download File
     

    Stentys drug-eluting self-expanding stent receives CE Marking

    05/05/2010

    Stentys drug-eluting self-expanding stent receives CE Marking

    PRINCETON, N.J., and PARIS, May 24, 2010—Stentys announced today that it has received CE Marking for its drug-eluting self-expanding stent.   
     

    Download File
     

    Stentys drug-eluting self-expanding coronary stent shows 4% restenosis in complex lesions

    07/02/2010

    Stentys drug-eluting self-expanding coronary stent shows 4% restenosis in complex lesions

    Long-term follow-up data in Stentys DES and BMS clinical study shows superior results in the treatment of bifurcations  


    PRINCETON, N.J., and PARIS, Feb. 15, 2010—Medical device pioneer Stentys announced today that the complete „OPEN-I‟ clinical study was presented by Stefan Verheye, M.D., Ph.D., at the Joint Interventional Meeting (“JIM”) 2010 in Rome, demonstrating superior results in 60 patients (27 Stentys drug-eluting stents and 33 Stentys bare-metal stents) who were followed–up angiographically after six months.  
     

    Download File
     

    STENTYS begins large-scale, “real life” study with its selfapposing stent for treatment of Heart Attacks

    09/12/2010

    STENTYS begins large-scale, “real life” study with its selfapposing stent for treatment of Heart Attacks  

    50 patients already enrolled

    PRINCETON, N.J., and PARIS, Dec. 09, 2010 — STENTYS S.A. (STNT.PA), which develops innovative stents to treat Acute Myocardial Infarction (AMI), announced today that it has begun the international APPOSITION III study of its self-apposing stent, with 50 patients already enrolled out of a total of 500. The trial primary endpoint is Major Adverse Cardiac Events at 12 months post-procedure.
     

    Download File
     

    Stentys completes enrollment in clinical study of its breakthrough stent to treat Acute Myocardial Infarction

    09/09/2010

    Stentys completes enrollment in clinical study of its breakthrough stent to treat Acute Myocardial Infarction

    International clinical trial could soon prove superiority of the novel stent over conventional techniques in a $5 billion market 


    PRINCETON, N.J., and PARIS, July 15, 2010—Stentys, which develops innovative stents to treat Acute Myocardial Infarction (AMI), announced today the enrolment of the final patient in the APPOSITION II clinical study—a randomized trial comparing the Stentys self-expanding stent with a conventional balloonexpandable stent in patients with AMI. The study results will be announced in September. 
     

    Download File
     

    Stentys self-apposing stent proves superior to conventional treatment of Acute Myocardial Infarction

    10/09/2010

    Stentys self-apposing stent proves superior to conventional treatment of Acute Myocardial Infarction

    APPOSITION II clinical trial highlights: 

    • After an infarction, 28% of patients treated with conventional stents displayed significant malapposition, a major cause of thrombotic events and severe complications; 

    • None of the patients treated with STENTYS self-apposing stent in the same conditions experienced ANY malapposition  


    PRINCETON, N.J., and PARIS, Sept.00, 2010—Stentys, which develops innovative stents to treat Acute Myocardial Infarction (AMI), announced today positive results from an international clinical trial, the APPOSITION II study
     

    Download File
     

    STENTYS appoints Michel Darnaud to its Board of Directors

    23/11/2010

    STENTYS appoints Michel Darnaud  to its Board of Directors

    PRINCETON, N.J., and PARIS, Nov. 23, 2010—STENTYS (STNT.PA), a medical technology company that markets a new generation of innovative stents to treat Acute Myocardial Infarction (AMI), announced today that its board of directors has nominated Michel Darnaud as a director. 
     

    Download File
     

    Stentys discloses results for world’s first clinical study to treat acute myocardial infarction (AMI) with a self-expanding stent

    15/09/2010

    Stentys discloses results for world’s first clinical study to treat acute myocardial infarction (AMI) with a self-expanding stent

    Adaptation to vessel growth with perfect apposition are key take-aways of the study   

    PRINCETON, N.J., and PARIS, Sept. 22, 2009—Medical device pioneer Stentys announced today the results on 20 patients participating in the Company’s ‘APPOSITION I’ clinical study—the world’s first to treat patients with acute myocardial infarction (AMI) via a selfexpanding stent. These data were disclosed today by the study’s principal investigator, Christian Spaulding, M.D., Ph.D., to an audience of cardiologists during a Stentys-hosted satellite meeting at the Transcatheter Cardiovascular Therapeutics (“TCT”) 2009 annual scientific meeting.
     

    Download File
     
  • 2009

     

    First patient enrolled in randomized study of STENTYS self-expanding stent vs. conventional stent to treat acute myocardial infarction (AMI).

    01/12/2009

    Download File
     

    STENTYS discloses results for world’s first clinical study to treat acute myocardial infarction (AMI) with a self-expanding stent.

    15/09/2009

    Download File
     

    STENTYS expands Scientific Advisory Board (SAB) on heels of reporting successful clinical trial results for world’s first self-expanding stent to treat AMI.

    31/10/2009

    Download File
     

Page ID 1288   |   Last edited 2017/10/16